-
Loading metrics
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
- Mohamed Osman,
- Anoop Mistry,
- Ada Keding,
-
Rhian Gabe,
Affiliation Department of Health Sciences, University of York, Heslington, York, United Kingdom
⨯ - Elizabeth Cook,
-
Sarah Forrester,
Affiliation Centre for Immunology and Infection, Dept. of Biology and Hull York Medical School, University of York, Heslington, York, United Kingdom
⨯ - Rebecca Wiggins,
- Stefania Di Marco,
- Stefano Colloca,
- Loredana Siani,
- Riccardo Cortese †,
- Deborah F. Smith,
- Toni Aebischer,
-
Paul M. Kaye ,
* E-mail: paul.kaye@york.ac.uk (PMK); charles.lacey@hyms.ac.uk (CJL)
Affiliation Centre for Immunology and Infection, Dept. of Biology and Hull York Medical School, University of York, Heslington, York, United Kingdom
⨯ - Charles J. Lacey
http://orcid.org/0000-0002-0273-3094
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
- Mohamed Osman,
- Anoop Mistry,
- Ada Keding,
- Rhian Gabe,
- Elizabeth Cook,
- Sarah Forrester,
- Rebecca Wiggins,
- Stefania Di Marco,
- Stefano Colloca,
- Loredana Siani
x
-
- Published: May 12, 2017
- https://doi.org/10.1371/journal.pntd.0005527